Palonosetron Information & Palonosetron Links at HealthHaven.com
advertise
add site
services
publishers
database
health videos
Bookmark and Share

search wiki for    ?
web dir firms image gallery news pdf wiki shop video 
about
toolbar
stats
live show
health store
more stuff
JOIN/LOGIN
Featured Results:
Aloxi (palonosetron) - Drug information from MediLexicon
Aloxi (palonosetron) - Drug information from MediLexicon
medilexicon.com
  Palonosetron (Injection) - Lenox Hill Hospital
Palonosetron (Injection) - Lenox Hill Hospital
lenoxhillhospital.org
 Infusion of Palonosetron Plus Dexamethasone for the Prevention of...
Infusion of Palonosetron Plus Dexamethasone for the Prevention of...
supportiveoncology.net
  Palonosetron (Injection)
Palonosetron (Injection)
quincymedgroup.com
 
Palonosetron
Systematic (IUPAC) name
(3aR)-2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,
4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one
Identifiers
CAS number 135729-61-2
ATC code A04AA05
PubChem 148211
DrugBank APRD00351
Chemical data
Formula C19H24N2O 
Mol. mass 296.407 g/mol
Pharmacokinetic data
Bioavailability 97% (oral)
Protein binding 62%
Metabolism Hepatic, 50% (mostly CYP2D6-mediated, CYP3A4 and CYP1A2 also involved)
Half life Approximately 40 hours
Excretion Renal, 80% (of which 49% unchanged); fecal (5 to 8%)
Therapeutic considerations
Licence data

US FDA:link

Pregnancy cat.

B1(AU) B(US)

Legal status

-only(US)

Routes Intravenous, oral


Palonosetron (INN, trade name Aloxi) is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV—nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy—and is the only drug of its class approved for this use by the U.S. Food and Drug Administration.[1] As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.

Palonosetron is administered intravenously, as a single dose, 30 minutes before chemotherapy,[1] or as a single oral capsule one hour before chemotherapy.[2] The oral formulation was approved on August 22, 2008 for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV.[2]

[edit] See also

[edit] References

  1. ^ a b De Leon A (2006). "Palonosetron (Aloxi): a second-generation 5-HT(3) receptor antagonist for chemotherapy-induced nausea and vomiting". Proceedings (Baylor University. Medical Center) 19 (4): 413–6. PMID 17106506.  Full text at PMC: 1618755.
  2. ^ a b Waknine, Yael (September 4, 2008). "FDA Approvals: Nplate, Aloxi, Vidaza". Medscape. http://www.medscape.com/viewarticle/580032. Retrieved 2008-09-04.  Freely available with registration.



Product Results (view all...)

search wiki for    ?
web dir firms image gallery news pdf wiki shop video 



↑ top of page ↑about thumbshots